Award
75A50126C00004
View source record on USAspending.gov ↗LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.
- Recipient
- SHIONOGI INC
- Awarding agency
- Department of Health and Human Services
- Sub-agency
- Office of Assistant Secretary for Preparedness and Response
- Fiscal year
- FY2026
- Obligated (promised)
- $119,160,691
- Total obligation (detail)
- $119,160,691
- Potential value (ceiling)
- $481,678,318
- Outlaid (paid out, linked File C)
- no linked financial data
- Signed
- Apr 6, 2026
- Period of performance
- Apr 6, 2026 – Mar 10, 2036
- Competition
- FULL AND OPEN COMPETITION
- Offers received
- 1
- Solicitation
- NEGOTIATED PROPOSAL/QUOTE
- Pricing
- COST PLUS FIXED FEE
- NAICS
- 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- Award type
- DEFINITIVE CONTRACT
Structural flags (1)
Competed award, single offer received
These contracts were officially open for any company to compete, but only one company showed up. Sometimes only one company really can do the job; sometimes the contest was set up so only one could win.
extent_competed=A · number_of_offers_received=1
Rule
single_bid_competed, methodology v1.2.0 — definition and caveats
Transactions (1)
| 0 | Apr 6, 2026 | — | $119,160,691 | LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS. |
Record history in our archive
Outlay keeps a content-hashed copy of this record from every pull. No post-publication revisions observed so far.
- detailfirst capture